恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

性别对免疫检查点抑制剂治疗晚期非小细胞肺癌疗效的影响-ag捕鱼平台

文字: 2019-10-23    浏览次数:407    

                                                          

 

abstract

immune checkpoint inhibitors (icis) have shown promising efficacy in the treatment of non-small cell lung cancer (nsclc). sex-associated dimorphism in immune system response is acknowledged, but the effect of patients’ sex on efficacy of icis as treatment in nsclc still remains controversial. the present study was conducted to investigate the difference in efficacy of nsclc patients receiving immune checkpoint inhibitors according to the sex.

免疫检查点抑制剂(icis)在非小细胞肺癌(nsclc)的治疗中显示出良好的疗效。虽然免疫系统反应中的性别相关二态性是公认的,但患者性别对icis治疗nsclc疗效的影响仍存在争议。本研究旨在探讨性别对icis治疗nsclc患者疗效的影响。

 

a total of 9583 patients involved 6567 men and 3016 women with advanced lung cancer from 15 randomized controlled trials were included in this study. 

共纳入15项随机对照试验的9583例晚期肺癌患者,其中男性6567例,女性3016例。

 

an overall survival (os) benefit of immune checkpoint inhibitors was illustrated in both male (hr 0.76, 95% ci 0.71-0.82) and female (hr 0.73, 95% ci 0.58-0.91) patients, and a progression-free survival (pfs) benefit was also found in both men (hr 0.67, 95% ci 0.58-0.77) and women (hr 0.73, 95% ci 0.56-0.95) in nsclc. both pd-1/pd-l1 inhibitors alone and pd-1/pd-l1 plus chemotherapy significantly improved the os and pfs in male patients. whereas in females, pd-1 inhibitors or monotherapy significantly benefited the os but not the pfs, pd-l1 inhibitors or combination therapy significantly prolonged the pfs but not the os. no survival benefit was found in both male and female patients from the ctla-4 inhibitors.

非小细胞肺癌男性和女性患者均从icis治疗中获益,其中,男性总生存期(os) (hr 0.76, 95% ci 0.71-0.82),女性os (hr 0.73, 95% ci 0.58-0.91);男性无进展生存期(pfs) (hr 0.67, 95% ci 0.58-0.77),女性pfs (hr 0.73, 95% ci 0.56-0.95)。单用pd-1/pd-l1抑制剂和pd-1/pd-l1联合化疗均能显著改善男性患者的ospfs。而在女性患者中,使用pd-1抑制剂或单药治疗对os有显著改善,但对pfs无显著改善;pd-l1抑制剂或联合治疗可显著延长pfs,但os无显著改善。ctla-4抑制剂对男性和女性患者均无生存获益。

 

the current study indicated that the magnitude of survival benefit is sex-dependent and male patients seemed to obtain more consistent and favorable outcomes from icis than women patients in nsclc.

研究表明,icis治疗nsclc患者的生存获益大小与性别有关,男性患者似乎能比女性患者获得更一致和有利的结局。